Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia

Hypertension in Pregnancy

Volumn 32, Issue 3, 2013, Pages 270-280

  Zhang, Lin ^a   Zhang, Zhan ^a   Gao, Yan ^a   Zhang, Linlin ^a   Jia, Liting ^a   Wang, Peng ^a   Li, He ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Glycoprotein 130; Interleukin 6; Interleukin 6R; Placenta; Preeclampsia

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTROPHOBLAST; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PLACENTA; PREECLAMPSIA; PREGNANCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNCYTIOTROPHOBLAST; UMBILICAL CORD; UPREGULATION;

ADULT; CASE-CONTROL STUDIES; CYTOKINE RECEPTOR GP130; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, INTERLEUKIN-6;

EID: 84881186206     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2013.798332     Document Type: Article

References (28)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33:130-7.
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44.
3. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-8.
4. Yang Z, Li R, Shi LY, et al. Clinical delimitation and expectant management of early onset of severe pre-eclampsia. Zhonghua Fu Chan Ke Za Zhi 2005;40:302-5.
5. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: Two different maternal hemodynamic states in the latent phase of the disease. Hypertension 2008;52:873-80.
6. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51:970-5.
7. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75:1-8.
8. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
9. Redman CW, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
10. Spooren A, Kolmus K, Laureys G, et al. Interleukin-6, a mental cytokine. Brain Res Rev 2011;67:157-83.
11. Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904-10.
12. Xie C, Yao MZ, Liu JB, Xiong LK. A meta-Analysis of tumor necrosis factor-Alpha, interleukin-6, and interleukin-10 in preeclampsia. Cytokine 2011;56:550-9.
13. Vic MJOV, Kovacevic T, Stefanoska I, Vicovac L. The effect of IL-6 on the trophobalst cell line HTR-8/SVneo. Arch Biol Sci 2010;62:531-8.
14. Jovanovic M, Vicovac L. Interleukin-6 stimulates cell migration, invasion and integrin expression in HTR-8/SVneo cell line. Placenta 2009;30:320-8.
15. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signaltransducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-Anchored gp130. Blood 1993;82:1120-6.
16. Wang Y, Lewis DF, Gu Y, et al. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension 2011;57:336-42.
17. Zhao S, Gu Y, Dong Q, et al. Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia. Placenta 2008;29:1024-8.
18. Lejie. Obstetrics and gynecology. 7th ed. Beijing: The People\rquote s Medical Publishing House; 2008.
19. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41.
20. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497-505.
21. Fitzgerald JS, Poehlmann TG, Schleussner E, Markert UR. Trophoblast invasion: The role of intracellular cytokine signalling via signal transducer and activator of transcription 3 (STAT3). Hum Reprod Update 2008;14:335-44.
22. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-Associated cancer. Cytokine Growth Factor Rev 2011;22:83-9.
23. Gaillard J, Pugniere M, Tresca J, et al. Interleukin-6 receptor signaling. II. Bioavailability of interleukin-6 in serum. Eur Cytokine Netw 1999;10:337-44.
24. Ndubuisi MI, Patel K, Rayanade RJ, et al. Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J Immunol 1998;160:494-501.
25. Modur V, Li Y, Zimmerman GA, et al. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 1997;100:2752-6.
26. Croker BA, Krebs DL, Zhang JG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003;4:540-5.
27. Qasimi P, Ming-Lum A, Ghanipour A, et al. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages. J Biol Chem 2006;281:6316-24.
28. Ma RQ, Sun MN, Yang Z. Effects of preeclampsia-like symptoms at early gestational stage on feto-placental outcomes in a mouse model. Chin Med J (Engl) 2010;123:707-12.